Pola‐R‐CHP for frontline therapy in DLBCL: Are we saving money by spending more?

Abstract

The study by Kambhampati et al. offers the first European perspective on cost‐effectiveness of pola‐R‐CHP in the frontline line treatment of DLBCL patients. Nevertheless, the applicability of these results in other European settings remain questionable: Germany is indeed a wealthy country with wide access to cellular therapies in earlier lines, while this might not be the case for other European countries. The presented data must be re‐assessed when long term data on PFS and OS from the POLARIX trial are available, ideally considering also real‐life data. Similar CEAs in other European health care systems as well as in specific subgroups of patients are welcome to offer a broader perspective on the potential role of pola‐R‐CHP in Europe.Commentary on: Kambhampati et al. Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola‐R‐CHP) in previously untreated diffuse large B‐cell lymphoma in Germany. Br J Haematol 2023;202:771–775.